CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Baricitinibdrug
Likely dose
Baricitinib 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03921554
NCT03921554Phase 2Completed
CompareCT.gov

Janus Kinase Inhibitor (Baricitinib) for Aicardi Goutières Syndrome

Adeline Vanderver, MD·interventional·Posted Apr 19, 2019·Updated Dec 30, 2025

In Brief

A Phase 2 clinical trial evaluating Baricitinib for Aicardi Goutieres Syndrome. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAicardi Goutieres Syndrome
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 19, 2019
Enrollment StartJun 3, 2019
Primary CompletionJan 4, 2024
Study CompletionMar 25, 2024
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 7.2 years ago

Interventions

Baricitinibdrug

Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.